chemTrailActivist · @chemTrailActivi
31st Dec 2013 from TwitLonger
#Morgellons #MorgellonsDisease #MD #BorrelialDermatitis
[MD news you can use -- I'm still not convinced there's a chemTrail - Morgellons connection. Let's get these people the meds they need.]
Morgellons: a novel dermatological perspective as the multisystem infective disease borreliosis
http://f1000research.com/articles/2-118/v1
Management and prognosis
There has been considerable debate about MD treatments.
To date, an exhaustive list of home remedies can be found on the internet, but evidence supporting the efficacy of these treatments is lacking.
Segments of the profession have tried therapy with antihelminthics including ivermectin, mebendazole, praziquantel and albendazole, but this approach as sole therapy is by and large ineffective and false conclusions as to their efficacy can be drawn by the cycling nature of the dermopathy.
No published material is available supporting such use.
The lead author has found that adequate treatment of B. burgdorferi will suppress and control the disorder, more easily so in earlier disease (unpublished observations).
Such treatment requires simultaneous antibiotic polypharmacy.
Cell wall drugs are useful for the extracellular spirochete forms, tetracyclines or macrolides are useful for the intracellular forms, while imidazole compounds such as metronidazole and tinidazole are useful for the cystic forms of B. burgdorferi.
In conjunction with LD treatment, the myriad associated coinfections need to be addressed including Anaplasma, Babesia, Bartonella, Ehrlichia and Rickettsia.
With advancing knowledge of cell-wall deficient forms of the Lyme spirochete, the mechanisms associated with chronic protracted LD are being understood, albeit slowly 41,42.
This knowledge also helps us to understand why skin examination looking only for spirochetes can be unrewarding as given the right conditions both the intracellular and cystic forms can morph back to a spirochetal form.
A recent study highlighted the significant burden of protracted LD patient care on healthcare systems 43, and delayed diagnosis of MD and LD adds to that burden.
We do not know if skin co-infections can be excluded at this juncture, nor can we rule out the possibility of co-factors playing a crucial role in filament formation.
These are areas for ongoing research as is the exact mechanism of filament production.
To date the long-term prognosis for protracted LD illness that includes MD remains unsettled.
[....]
Research needs to be directed at identifying the fundamental flaw in filament production at the cellular level, which may involve RNA/DNA dysfunction, in the hope of addressing further treatment.